Samsung Biologics has secured its place in the Dow Jones Best-in-Class World Index (DJBIC), a globally recognized Environmental, Social, and Governance (ESG) evaluation metric, for the fifth consecutive year.

Industry reports on May 9 revealed that Samsung Biologics has maintained its position in this prestigious index annually from 2021 through last year.

The DJBIC, published by S&P Global, is a comprehensive ESG assessment tool that evaluates approximately 2,500 of the world's highest market cap companies. It ranks businesses based on their economic performance and ESG achievements, with only the top 10% making the cut.

Samsung Biologics earned recognition for its balanced improvements across all ESG domains, bolstering its management systems and execution capabilities. The company notably achieved world-class ratings in critical areas such as supply chain management, energy and water conservation, and workplace safety.

On the environmental front, Samsung Biologics has implemented a robust carbon emissions management system. This includes setting specific energy conservation and greenhouse gas reduction targets, as well as introducing an internal carbon pricing mechanism.

In terms of social responsibility, the company has enhanced its ESG policy implementation through ethical marketing practices, advanced information security systems, and programs designed to boost digital competencies.

Regarding governance, Samsung Biologics has adopted a supply chain evaluation framework aligned with global standards, including the Responsible Business Alliance (RBA) initiative. The company has also developed a comprehensive screening system to manage supply chain risks. Furthermore, it has upgraded its product quality management processes and committed to transparent disclosure of relevant information.

As pharmaceutical giants worldwide increasingly apply ESG standards across their supply chains, Samsung Biologics' ESG capabilities in its contract development and manufacturing (CDMO) operations are viewed as crucial for meeting client expectations.

John Lim, Chief Executive Officer (CEO) of Samsung Biologics, commented that its consistent inclusion in the DJBIC World Index for five straight years reaffirms the position as a global ESG leader. They're committed to proactively addressing the clients' ESG requirements and further enhancing the sustainable management practices.

Samsung Biologics has secured its place in the Dow Jones Best-in-Class World Index (DJBIC) …

Samsung Biologics Named Dow Jones Best-in-Class World Index for Fifth Straight Year